Karen L. Kelly was appointed chief executive officer of the International Association for the Study of Lung Cancer, effective spring 2022.
The Goldstein familyRuth “Rikki” Kutcher Goldstein made a $2 million gift to support cancer research at Indiana University School of Medicine.
The American Lung Association’s 4th annual “State of Lung Cancer” report showed that the lung cancer five-year survival rate increased 14.5% nationally to 23.7% yet remains significantly lower among communities of color.
Routine screening procedures for breast, colon, and cervical cancers in the first half of 2021 have failed to recover, falling by about a third below historical baselines, even as Americans are resuming normal activities.
From 2015 to 2018, the overall cancer death rate in the United States fell by 2.3% per year for men and 2.1% per year for women—an unprecedented drop, led by accelerated decline in deaths from lung cancer and melanoma.
Patients with early stage lung cancer live longer when they receive a lobectomy rather than a less extensive operation or radiation treatment, according to a study published in The Annals of Thoracic Surgery.
Genentech said the phase III IMpower150 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer.
A recent study confirmed the International Association for the Study of Lung Cancer's proposed criteria for uncertain resection margin status, R(un), in residual tumor (R) classification.
Bristol-Myers Squibb announced three-year overall survival data from CheckMate-017 and CheckMate-057, two pivotal phase III randomized studies evaluating Opdivo versus docetaxel in patients with previously treated metastatic non-small cell lung cancer.
Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone of Ohio State University Comprehensive Cancer–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
